Treatment of patients with high risk DLBCL

被引：0
|
作者：
Keller, U. [1 ]
机构：
[1] Tech Univ Munich, Innere Med 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V105
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [21] Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
    Rungwittayatiwat, Sirapat
    Boonsakan, Paisarn
    Chantrathammachart, Pichika
    Puavilai, Teeraya
    Pukiat, Sulada
    Phusanti, Sithakom
    Boonyawat, Kochawan
    Wacharapornin, Pathawut
    Angchaisuksiri, Pantep
    Ungkanont, Artit
    Chuncharunee, Suporn
    Niparuck, Pimjai
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
  • [22] FEASIBILITY OF ANTHRACYCLINE BASED TREATMENT IN UNSELECTED ELDERLY DLBCL PATIENTS
    Melchardt, T.
    Weiss, L.
    Hufnagl, C.
    Neureiter, D.
    Kemmerling, R.
    Hopfinger, G.
    Greil, R.
    Egle, A.
    HAEMATOLOGICA, 2012, 97 : 669 - 669
  • [23] Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup
    Jiang, Shiyu
    Qin, Yan
    Jiang, Hongxin
    Liu, Biao
    Shi, Jianming
    Meng, Fanlu
    Liu, Peng
    Yang, Jianliang
    Yang, Sheng
    He, Xiaohui
    Zhou, Shengyu
    Gui, Lin
    Liu, Hao
    Lin, Jing
    Han Han-Zhang
    Shi, Yuankai
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) : 2611 - 2620
  • [24] Feasibility of anthracycline based treatment in unselected elderly DLBCL patients
    Melchardt, T.
    Weiss, L.
    Hufnagl, C.
    Neureiter, D.
    Kemmerling, R.
    Hopfinger, G.
    Greil, R.
    Egle, A.
    ONKOLOGIE, 2012, 35 : 86 - 87
  • [25] Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients
    Diamond, Akiva
    Ayyappan, Sabarish
    Cao, Shufen
    Tashtish, Nour
    Boughan, Kirsten M.
    Cooper, Brenda W.
    Fu, Pingfu
    Caimi, Paolo F.
    BLOOD, 2021, 138
  • [26] Upfront intensification incorporating dose dense rituximab and high dose MTX to CHOP-14 in young high risk DLBCL patients
    Struessmann, T.
    Fritsch, K.
    Fietz, T.
    Finke, J.
    Marks, R.
    Oncology Research and Treatment, 2015, 38 : 198 - 198
  • [27] Optimization of Rituximab for Treatment of DLBCL in Young, High-Risk Patients-Results of the Dense-R-CHOEP Trial of the German High-Grade Lymphoma Study Group
    Schmitz, Norbert
    Nickelsen, Maike
    Ziepert, Marita
    Haenel, Mathias
    Viardot, Andreas
    Dreyling, Martin H.
    Borchmann, Peter
    Bokemeyer, Carsten
    Peschel, Christian
    Wolf, Hans-Heinrich
    Mahlberg, Rolf
    Pfreundschuh, Michael
    Glass, Bertram
    BLOOD, 2015, 126 (23)
  • [28] Treatment of Diffuse Large Cell Lymphoma (DLBCL) Patients Older Than 75 Years: Higher Mortality and Risk of Complications without Increased Risk of Relapse after Treatment
    Diamond, Akiva
    Ayyappan, Sabarish Ram
    Pinto, Raisa
    Malek, Ehsan
    Tomlinson, Ben K.
    Metheny, Leland
    Cooper, Brenda
    Gerson, Stanton L.
    Lazarus, Hillard M.
    De Lima, Marcos
    Caimi, Paolo F.
    BLOOD, 2016, 128 (22)
  • [29] Treatment of the depressive patients at clinical high risk for psychsis
    Omelchenko, M.
    EUROPEAN PSYCHIATRY, 2022, 65 : S270 - S270
  • [30] High-risk patients: modern treatment strategy
    Nebieridze, D. V.
    Meliya, A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2010, 9 (06): : 97 - 101
12345